Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follitropin delta + triptorelin
- Development stage
- Phase 3
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
FE 999049 (follitropin delta) is a novel recombinant human follicle-stimulating hormone (rFSH) developed by Ferring Pharmaceuticals and marketed under the brand name REKOVELLE. It is indicated for controlled ovarian stimulation to develop multiple follicles in women undergoing assisted reproductive technologies such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). FE 999049 is dosed individually based on body weight and serum anti-Müllerian hormone levels[5][6]. Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone-releasing hormone (LHRH), classified as a gonadotropin-releasing hormone (GnRH) agonist. It acts by initially stimulating and then suppressing pituitary secretion of LH and FSH after chronic administration[3][7]. The combination of follitropin delta with triptorelin may be used in protocols for ovarian stimulation where GnRH agonists are employed to prevent premature ovulation.
- Brand names
- Rekovelle + GonapeptylRekovelle + Decapeptyl
- Other names
- recombinant human follicle-stimulating hormone + triptorelin
02
Targets
FSHR (Follicle-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on follitropin delta + triptorelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follitropin delta + triptorelin.